APTO:NSD-Aptose Biosciences Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.92

Change

-0.57 (-10.38)%

Market Cap

USD 0.49B

Volume

2.18M

Average Target Price

USD 11.50 (+133.74%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-10.75 (-6.19%)

USD69.53B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.98 (-0.46%)

USD55.62B 20.48 15.19
REGN Regeneron Pharmaceuticals, Inc

-2.76 (-0.57%)

USD51.68B 15.90 12.28
BNTX BioNTech SE

-6.11 (-3.45%)

USD50.45B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.42 (+0.84%)

USD37.30B 54.77 36.21
BGNE BeiGene, Ltd

-4.85 (-1.56%)

USD29.11B N/A N/A
RPRX Royalty Pharma plc

-0.65 (-1.53%)

USD25.78B 22.60 15.82
SGEN Seagen Inc

-1.11 (-0.82%)

USD24.72B 38.00 35.77
GMAB Genmab A/S

+1.09 (+3.06%)

USD24.27B 26.59 3.52
CVAC CureVac N.V

-7.93 (-7.27%)

USD22.38B N/A N/A

ETFs Containing APTO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.33% 69% D+ 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.33% 69% D+ 59% F
Trailing 12 Months  
Capital Gain -33.42% 20% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.42% 20% F 6% F
Trailing 5 Years  
Capital Gain 97.59% 72% C- 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.59% 72% C- 64% D
Average Annual (5 Year Horizon)  
Capital Gain 70.33% 84% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.33% 84% B 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 111.03% 23% F 13% F
Risk Adjusted Return 63.34% 87% B+ 80% B-
Market Capitalization 0.49B 56% F 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.21 56% F 41% F
Price / Cash Flow Ratio -14.51 68% D+ 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -51.91% 57% F 23% F
Return on Invested Capital -52.40% 46% F 16% F
Return on Assets -30.75% 40% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.37 91% A- 84% B
Short Percent 4.17% 68% D+ 44% F
Beta 1.30 56% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector